Goldman Sachs cuts Chemours stock price target on EBITDA outlook
Goldman Sachs reduced its price target for Chemours (NYSE:CC) to $16 from $17, maintaining a Neutral rating. The firm cited a 12-month outlook and potential risks, including pricing volatility and regulatory costs. Chemours shares are down 36% over six months but up 19% year-to-date. The company reported mixed Q2 2026 results, missing earnings and revenue estimates. UBS also downgraded Chemours to Neutral, citing concerns over its refrigerant business.
How this was made
The 30-second read
Why it matters
The downgrade reflects concerns over earnings miss and PFAS liabilities, likely prompting short‑term selling pressure.
Market read
Analyst downgrade with a new price target is a material catalyst for Chemours, affecting its valuation and potentially influencing peers in the chemicals space.
What to watch
Potential upside from titanium technologies pricing and Opteon refrigerant adoption may be under‑appreciated.
Background
Goldman Sachs adjusted its valuation multiple for Chemours and highlighted both upside and downside risks, including regulatory and litigation factors.
Ticker impact
Goldman Sachs lowered Chemours' price target to $16 and kept a Neutral rating, citing mixed Q2 results and PFAS liability risks.
likely pressure as the market prices in the lower target and heightened PFAS risks
The downgrade is a fresh analyst action with a concrete new target, which typically moves the stock on the day of release.
Market effects
Chemours' PFAS liability concerns may weigh on the broader specialty chemicals sector.
U.S. chemical stocks could see modest weakness.
Limited to investors tracking U.S. specialty chemicals.
Counterpoint
If PFAS litigation resolves favorably, the stock could rebound despite the downgrade.
Key entities
- analystGoldman Sachs
Provided the new price target and rating.
- companyChemours Co.
Specialty chemicals manufacturer subject of the downgrade.
